Dr. Fairfield T. Bain

Dr. Fairfield T. Bain

DVM, MBA, Dipl. ACVIM, ACVP, ACVECC,
Associate Director of Strategic Development
and Innovation – Equine

Dr. Fairfield Bain is the Associate Director of Strategic Development and Innovation – equine, spearheading Merck Animal Health’s business development and research for the horse. Bain has an extensive background in both academia and practice.

Dr. Bain received his Doctor of Veterinary Medicine from Auburn University. He began his career as an intern at North Carolina State University, followed by an internal medicine residency at the University of Florida and a pathology residency at Kansas State University. He was a lecturer in medicine at New Bolton Center, fellow in comparative pathology at Wake Forest University, and associate professor, senior clinician at The University of Queensland, Australia. Prior to joining Merck Animal Health in 2016, he served as clinical professor of equine internal medicine and equine section head at Washington State University.



I enjoy people who are always looking for something innovative. We are fortunate to have many customers like that who come to us with ideas.



Over the years, Dr. Bain has amassed significant clinical experience at several equine referral hospitals. He also spent 12 years as co-owner and vice president of a worldwide manufacturer and distributor of hyperbaric oxygen chambers for veterinary applications.

When not in the field, Dr. Bain enjoys traveling with his wife, perfecting his archery and photography skills and learning about Southwestern history and cuisine.

Areas of Interest

  • Diagnostic Ultrasound in Critical Care
  • Perinatology and Neonatal Intensive Care
  • Cardiovascular Disorders
  • Cytopathology and Surgical Pathology
  • Dermatology and Dermatopathology
  • Hyperbaric Oxygen Therapy

Publications

  • “Prevalence Factors Associated with Equine Influenza Virus Infection in Equids with Upper Respiratory Tract Infection from 2008 to 2019” (AAEP Proceedings 2019)
  • “Prevalence factors associated with EHV-2/5 among equines with signs of upper respiratory infection in the US” (ACVIM abstract 2017)
  • “Prevalence factors associated with equine herpesvirus type 1 infection in equids with upper respiratory tract infection and/or acute onset of neurological signs from 2008 to 2014” (Vet Rec 2015)
  • “Ultrasonographic visualization of colonic mesenteric vasculature as an indicator of large colon right dorsal displacement or 180º volvulus (or both) in horses.” (Canadian Veterinary Journal, 2012)
  • “Equine Fetal Growth and Development.” (Compendium on Continuing Education for the Practicing Veterinarian, 2003)
  • “Effect of hydroxyethyl starch infusion on colloid oncotic pressure in hypoproteinemic horses.” (Journal of the American Veterinary Medical Association, 2001)
  • “Congenital defects in newborn foals of mares treated for equine protozoal myeloencephalitis during pregnancy.” (Journal of the American Veterinary Medical Association, 1998)